Michelle Xia represents a rising generation of biotech companies in China challenging Western giants.

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Merck & Co has passed another milestone in its drive to move PD-1 inhibitor Keytruda earlier in the treatment pathway for cancer, with the European Commission approving use of the drug as post ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE: MRK) stands against other stocks that Jim Cramer discussed recently. On Wednesday, Jim Cramer, the host of Mad Money ...

We recently published a list of Jim Cramer Recently Talked About These 9 Stocks. In this article, we are going to take a look ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We recently published a list of 10 Defensive Stocks Billionaire Ken Fisher is Betting On. In this article, we are going to ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness ...

March 03, 2025--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, London and The ...

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 10, 2025. REUTERS/Jeenah Moon/File Photo Investors pulled out of U.S. bond funds heavily in the week ...